Acta Scientific Microbiology (ISSN: 2581-3226)

Short CommunicationVolume 4 Issue 10

Third Doses (Booster) of COVID-19 Vaccination

Attapon Cheepsattayakorn1,2*, Ruangrong Cheepsattayakorn3 and Porntep Siriwanarangsun1

1Faculty of Medicine, Western University, Pathumtani Province, Thailand
210th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand
3Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

*Corresponding Author: Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand.

Received: August 09, 2021;; Published: 00-00

Citation: Attapon Cheepsattayakorn., et al. “Third Doses (Booster) of COVID-19 Vaccination". Acta Scientific Microbiology 4.10 (2021): 27-28.

  Flaxman., et al. a groups of investigators from the University of Oxford, United Kingdom demonstrated the results studied in COVID-19-vaccinated participants in a preprint published on June 28, 2021 that for those who had 8 to 12 week (median age 39), 15 to 25 week (median age 36), and 44 to 45 week (median age 32) intervals between the first and second COVID-19-vaccine doses, the median level of IgG antibody at the day 28 after the second dose were 923, 1,860, and 3,738 tIgG EU, respectively [1]. These results indicated the longer dose intervals the higher IgG-antibody levels [1]. They identified the median 278 and 1,240 tIgG EU in the groups who had a 8 to 12 week and a 15 to 25 week intervals, respectively after 6 months of the second dose, whereas the data for the 44 to 45 week-interval group are not yet available [1]. After the second dose, the IgG binding titers to the four SARS-CoV-2 (COVID-19) variants (alpha, beta, delta, and D614G) tested were significant higher than before the second dose [1]. Among 75 first-two-dose-received participants with an interval of 8 to 16 weeks, the IgG antibody levels were 1,792 and 3,746 tIgG EU at the day 28 after the second dose and after the third (boosted) dose, respectively [1].

Bibliography

  1. Flaxman A., et al. “Tolerability and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 (AZD1222)”. SSRN (Preprint) (2021).
  2. Mahase E. “COVID-19: Booster vaccine to be rolled out in authum as a UK secures 60m more Pfizer doses”. BMJ 373 (2021): n1116.
  3. Mahase E. “COVID-19: third vaccine dose boosts immune response but may not be needed, say researchers”. BMJ 373 (2021): n1659.
  4. Fuentes V and Malinowski M. “Bloomberg. Prognosis: Chile rolls out COVID-19 booster push that mixes vaccines”. Updated on August 6 (2021).
  5. News. Posted on July 30, 2021. COVID-19 boosters for wealthy nations spark outrage (2021).

Copyright: © 2021 Attapon Cheepsattayakorn., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is October 20, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US